Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):e47-e49. doi: 10.1097/QAI.0000000000002153.

Abstract

Supplemental Digital Content is Available in the Text.

Publication types

  • Clinical Trial, Phase II
  • Multicenter Study

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Drug Resistance, Viral / genetics
  • Female
  • HIV Infections / drug therapy*
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • Humans
  • Lamivudine / administration & dosage
  • Male
  • Middle Aged
  • Mutation*
  • Pyridones / administration & dosage
  • RNA, Viral / analysis
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Tenofovir / administration & dosage
  • Triazoles / administration & dosage

Substances

  • Anti-HIV Agents
  • Pyridones
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Triazoles
  • Lamivudine
  • doravirine
  • Tenofovir